JP2009507835A5 - - Google Patents

Download PDF

Info

Publication number
JP2009507835A5
JP2009507835A5 JP2008530022A JP2008530022A JP2009507835A5 JP 2009507835 A5 JP2009507835 A5 JP 2009507835A5 JP 2008530022 A JP2008530022 A JP 2008530022A JP 2008530022 A JP2008530022 A JP 2008530022A JP 2009507835 A5 JP2009507835 A5 JP 2009507835A5
Authority
JP
Japan
Prior art keywords
neuritin
composition
antibody
vector
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008530022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009507835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/035324 external-priority patent/WO2007030820A2/en
Publication of JP2009507835A publication Critical patent/JP2009507835A/ja
Publication of JP2009507835A5 publication Critical patent/JP2009507835A5/ja
Pending legal-status Critical Current

Links

JP2008530022A 2005-09-09 2006-09-11 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 Pending JP2009507835A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71576605P 2005-09-09 2005-09-09
PCT/US2006/035324 WO2007030820A2 (en) 2005-09-09 2006-09-11 Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013239723A Division JP6019334B2 (ja) 2005-09-09 2013-11-20 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作

Publications (2)

Publication Number Publication Date
JP2009507835A JP2009507835A (ja) 2009-02-26
JP2009507835A5 true JP2009507835A5 (cg-RX-API-DMAC10.html) 2009-11-05

Family

ID=37836580

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008530022A Pending JP2009507835A (ja) 2005-09-09 2006-09-11 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
JP2013239723A Expired - Fee Related JP6019334B2 (ja) 2005-09-09 2013-11-20 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
JP2016083897A Pending JP2016183163A (ja) 2005-09-09 2016-04-19 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
JP2018089059A Pending JP2018197227A (ja) 2005-09-09 2018-05-07 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013239723A Expired - Fee Related JP6019334B2 (ja) 2005-09-09 2013-11-20 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
JP2016083897A Pending JP2016183163A (ja) 2005-09-09 2016-04-19 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
JP2018089059A Pending JP2018197227A (ja) 2005-09-09 2018-05-07 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作

Country Status (6)

Country Link
US (1) US20100040636A1 (cg-RX-API-DMAC10.html)
EP (2) EP3031470A3 (cg-RX-API-DMAC10.html)
JP (4) JP2009507835A (cg-RX-API-DMAC10.html)
AU (1) AU2006287315B2 (cg-RX-API-DMAC10.html)
CA (1) CA2621992C (cg-RX-API-DMAC10.html)
WO (1) WO2007030820A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132357A1 (en) * 2008-04-25 2009-10-29 New York Blood Center, Inc. Abi1/hssh3bp1 conditional knockout mouse
EP2691515A2 (en) * 2011-03-31 2014-02-05 President and Fellows of Harvard College A unique population of regulatory t cells that regulate tissue regeneration and wound healing
US20150258096A1 (en) * 2012-10-10 2015-09-17 The Regents Of The University Of California Methods and compositions for treatment of th2-mediated and th17-mediated diseases
ES2935257T3 (es) 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
KR101941004B1 (ko) * 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
US9926565B2 (en) * 2014-09-23 2018-03-27 Oregon Health & Science University Aptamer-RNAi therapeutic compositions
WO2019040994A1 (en) * 2017-09-01 2019-03-07 The Australian National University IMMUNOREGULATOR MOLECULES AND USES THEREOF
WO2020146772A1 (en) * 2019-01-11 2020-07-16 The Johns Hopkins University Neuritin regulation of t cell anergy and t regulatory cell function
WO2025241119A1 (zh) * 2024-05-22 2025-11-27 深圳理工大学(筹) 融合蛋白及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE69034263D1 (de) 1989-07-25 2009-04-02 Cell Genesys Inc Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991012650A1 (fr) 1990-02-09 1991-08-22 Asulab S.A. Micromoteur electrostatique a champ radial realise par microfabrication photolithographique et procede de realisation d'un tel micromoteur
EP0464533B1 (de) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
NZ243090A (en) 1991-06-18 1993-11-25 Lilly Co Eli Method of identifying active peptides and synthesis of peptide mixtures with a known amino acid in the last coupled position
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5817784A (en) * 1996-08-09 1998-10-06 Amgen Inc. Neurogene
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP2003524406A (ja) * 1999-06-02 2003-08-19 ジェネンテック・インコーポレーテッド 腫瘍細胞成長阻害のための組成物及び方法
US20030143228A1 (en) * 2001-10-29 2003-07-31 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen
WO2004031347A2 (en) * 2002-09-24 2004-04-15 Massachusetts Institute Of Technology Methods and compositions for soluble cpg15
WO2004028479A2 (en) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
WO2004062591A2 (en) * 2003-01-06 2004-07-29 Oregon Health And Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases
JP2007538000A (ja) * 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性ｔ細胞は自己免疫を抑制する

Similar Documents

Publication Publication Date Title
Seyfrid et al. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
Tran et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
JP7696658B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
Omer-Javed et al. Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells
JP6683990B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
Look et al. CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines
JP2021151249A (ja) 腫瘍抗原ｎｙ−ｅｓｏ−１のｍｈｃ ｉおよびｍｈｃ ｉｉ拘束性エピトープに対する、癌の併用ｔ細胞受容体遺伝子療法
CN110872577A (zh) 修饰的免疫细胞及其应用
JP6942466B2 (ja) 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法
CN114174495A (zh) 肿瘤浸润淋巴细胞疗法及其用途
JP2022511735A5 (cg-RX-API-DMAC10.html)
ES2967879T3 (es) Mejora de la actividad de los linfocitos T citolíticos mediante la inhibición de EBAG9
CN110627909A (zh) 一种特异性活化nk细胞的嵌合抗原受体及其应用
WO2024017362A1 (zh) 靶向gprc5d和/或bcma的嵌合抗原受体及其应用
Niu et al. Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells
CN116103240A (zh) 增强免疫细胞持久性的方法
US20240058447A1 (en) Use of fusion constructs for il-2 independent t cell therapy
Deuse et al. Immunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells
Xiong et al. CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors
Chantzoura et al. The allogeneic FAP-CAR-IL15 iNKT therapy MiNK-215 remodels the tumor stroma to enhance antitumor immunity
CN121263436A (zh) 用于治疗病症的工程化免疫细胞，构造及其方法
CN112262212B (zh) 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
Qie et al. Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells
WO2023076811A1 (en) Combination therapies with chimeric antigen receptors
EP3914268B1 (en) A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject